Form 8-K - Current report:
SEC Accession No. 0001493152-24-044891
Filing Date
2024-11-13
Accepted
2024-11-12 17:40:03
Documents
20
Period of Report
2024-11-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51739
2 ex1-1.htm EX-1.1 527313
3 ex5-1.htm EX-5.1 24342
4 ex99-1.htm EX-99.1 14997
5 ex99-2.htm EX-99.2 13171
6 ex5-1_001.jpg GRAPHIC 72422
7 ex99-1_001.jpg GRAPHIC 43006
  Complete submission text file 0001493152-24-044891.txt   1090976

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE prph-20241107.xsd EX-101.SCH 3027
9 XBRL LABEL FILE prph-20241107_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE prph-20241107_pre.xml EX-101.PRE 24173
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3683
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 241450144
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)